Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (1): 7-15    DOI: 10.12892/ejgo4266.2019
Review | Next articles
The role of erythropoietin and erythropoietin receptor expression in breast cancer
M.P. Budzik1, *(), A.M. Badowska-Kozakiewicz1
1Department of Biophysics and Human Physiology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland
Download:  PDF(689KB)  ( 210 ) Full text   ( 42 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Erythropoietin (EPO) plays a number of important functions in the body. Contrary to original beliefs, its activity is not limited to exerting effects on cells along the erythropoietic pathway. Newly published results continue to provide information on novel functions of the protein in other types of tissues, as well as on the important roles played by EPO in pathological processes. With no doubt, EPO has a significant impact on the biology of breast cancer cells by affecting cells’ proliferation, apoptosis, resistance to chemotherapy, as well as expression of various types of receptors. EPO exerts its direct action on breast cancer stem-like cells by activation of specific signaling pathways responsible for protection of the tumor from chemotherapy and accelerating disease progression. EPO could inhibit chemotherapeutic drug-induced apoptosis and cytotoxicity. Its correlation with tissue hypoxia may play a significant role in the therapeutic resistance of hypoxic tumors. In recent years, the role of endogenous EPO in regulation of carcinogenesis was also noted. Exogenous EPO, in the form of rhEPO, had been introduced with best intention to treat patients with cancer-related anemia in the course of breast cancer. While it decreases the transfusion requirements and improves the quality of life of cancer patients, randomized trials have demonstrated that rhEPO administration is associated with shorter progression-free and overall survival. Observations allow also to say that EPO antagonizes treatment with the anti-HER2 antibody trastuzumab by activating EpoR/JAK2 downstream effectors, effectively bypassing HER2 signaling. Although increasing amount of information is available regarding the role of EPO and EpoR in breast cancer, elucidation of the activity and involvement of these proteins in complex processes occurring within the cancer cells requires extensive research. Every set of results being published answers some of the questions while instead raise new ones.

Key words:  Breast neoplasms      Erythropoietin      Hypoxia     
Published:  10 February 2019     
*Corresponding Author(s):  M.P. BUDZIK     E-mail:  michalbudzik.5@gmail.com

Cite this article: 

M.P. Budzik, A.M. Badowska-Kozakiewicz. The role of erythropoietin and erythropoietin receptor expression in breast cancer. European Journal of Gynaecological Oncology, 2019, 40(1): 7-15.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4266.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I1/7

[1] M.-C. Tung, F.-Wei Chang, T.-P. Fan, J. Jin, Y.-K. Chang, Y.-C. Chen, H.-C. Fan. Acidity is one of the main mechanism for hypoxia triggering chemoresistance to mitoxanthrone (MX) in the human breast cancer MCF-7 cell line[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 994-999.
[2] F.V. Carvalho Sousa Esteves, L.A. Gomes de Sousa, R.S. Martins, A.L. Ramos Bezerra de Alencar, L. de Deus Sousa, M.C. Cronemberger Guimarães Serzedo, I. Meneses de Carvalho Coelho, S.C. Vieira. Paget’s disease of the breast after nipple-areola sparing mastectomy: case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1087-1090.
[3] A. Markowska, A. Huczyński, Z. Kojs, D. Twardawa, J. Markowska. Hypoxia and its importance in the course of gynaecological cancers[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 711-713.
[4] S. Dong Soo, P. Won Young, K. Ki Hyung, K. Ahrong, K. Young Keum, K. Kyungbin, C. Kyung Un. Differential regulation and prognostic significance of endogenous hypoxic markers in endometrial carcinomas[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 773-778.
[5] K. Favere, S. Menon, K. Valentine, J. Bogers, D. Vanden Broeck. Human papillomavirus prevalence and breast carcinogenesis: a systematic review and meta-analysis of published literature[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 161-173.
[6] C. Cedolini, S. Bertozzi, A. P. Londero, M. Yanova, L. Seriau, S. Bernardi, A. Risaliti. Clinicopathological characteristics and outcome of high grade breast cancer: our 9 years' experience[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 708-714.
[7] C.D. Chen, L.N. Dai, M. Wang, X.H. Lai, J. Wang. Hypoxia induces autophagy in PA-1 ovarian teratoma cells and resistance to growth inhibition and apoptosis by chemotherapeutic agent cis-diamminedichloroplatinum[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 277-281.
No Suggested Reading articles found!